FDA OKs Oxoid's rapid antimicrobial susceptibility test:
This article was originally published in Clinica
Executive Summary
Oxoid has received US FDA 510(k) clearance to market its antimicrobial susceptibility test for detecting oxacillin/methicillin resistance. The PBP2' test, which identifies MRSA and MRCoNS, is the first rapid latex test to gain the nod in the US for confirming both Staphylococcus aureus and coagulase negative staphylococci, claims the Basingstoke, UK firm. Moreover, the company adds, the PBP2' test has demonstrated an accuracy of 100% compared with PCR.